Opinion
Video
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
Author(s):
Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency.
Video Player is loading.
Clinical Implications for PSA Monitoring
Key Themes:
- Real-world implications for urologists monitoring patients on darolutamide plus ADT
- Importance of sensitive PSA assays
- Potential for PSA kinetics to guide treatment decisions
Expert Insights:
- Dr Shore provided guidance on how these findings might influence the way urologists monitor and interpret PSA trends in patients receiving darolutamide plus ADT.
He emphasized the importance of using appropriately sensitive assays and how PSA kinetics could inform treatment intensity or surveillance strategies.
Related Videos
Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
Fred Saad, MD, FRCP, reacts to FDA approval of darolutamide in mCSPC
The Role of Bone-Targeted Therapies
Topline Results From Recent NMIBC Trials
Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs
First-Line mHSPC Therapy: AR Inhibitors vs Chemotherapy
Using Ultrasensitive PSA Assays in Routine Practice
Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
Outcomes in Black patients receiving darolutamide plus ADT for mHSPC
Related Content
